3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Dermatologic
1
CNS
1
Conditions
Carcinoma, Hepatocellular
8
Uveal Melanoma
1
Stomach Neoplasms
1
Resectable Hepatocellular Carcinoma
1
Neoplasms
1
Liver Neoplasms
1
Glioma
1
Colorectal Neoplasms
1
Carcinoma
1
Advanced Pancreatic Cancer
1
Interventions
Gemcitabine
11
pembrolizumab
10
Oxaliplatin
7
Nivolumab
7
Irinotecan
7
Fluorouracil
7
Capecitabine
7
durvalumab
6
Sorafenib
6
Leucovorin
6
Cyclophosphamide
6
Paclitaxel
5
Ipilimumab
5
tislelizumab
3
poly ICLC
3
lenvatinib
3
fludarabine
3
Sunitinib
3
Radiotherapy
3
Cisplatin
3
Cetuximab
3
130-nm albumin-bound paclitaxel
3
seocalcitol
2
selinexor
2
pemigatinib
2
futuximab
2
fludarabine phosphate
2
donafenib
2
cemiplimab
2
atezolizumab
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma
×
ADI PEG20
×
Gastrointestinal
×
Clear all
NCT02029690
2020-09-25
TRAP
Polaris Group
Phase 1
Terminated
85 enrolled